“…revealed a 16% requirement of NIV support in COVID-19 patients with chronic respiratory diseases [ 19 ]. NIV is suggested in COPD patients (having COVID-19) with acute hypoxemic respiratory failure if oxygen therapy fails [ 23 ]. As patients with COPD have a higher risk of developing a severe COVID-19 disease requiring oxygen therapy, the need for mechanical ventilator support also becomes higher in this group.…”
Background: Although COPD is not one of the most common comorbidities in COVID-19 patients, it can be more fatal in this group. This study aimed to investigate the characteristics and prognosis of COPD patients among the population with COVID-19. Research design and methods: Patients diagnosed with positive PCR test were included in our multicentered, retrospective study. Patients with airway obstruction (previous spirometry) were included in 'COPD group'. Results: The prevalence of COPD in COVID-19 patients was 4.96%(53/1069). There was a significant difference between COPD and non-COPD COVID-19 patients in terms of gender, mean age, presence of dyspnea, tachypnea, tachycardia, hypoxemia and presence of pneumonia. The mortality rate was 13.2% in COPD, 7% in non-COPD patients(p = 0.092). The significant predictors of mortality were higher age, lymphopenia (p < 0.001), hypoxemia (p = 0.028), high D-dimer level (p = 0.011), and presence of pneumonia (p = 0.043) in COVID-19 patients. Conclusions: Our research is one of the first studies investigating characteristics of COPD patients with COVID-19 in Turkey. Although COPD patients had some poor prognostic features, there was no statistical difference between overall survival rates of two groups. Age, status of oxygenization, serum D-dimer level, lymphocyte count and pneumonia were significantly associated parameters with mortality in COVID-19.
“…revealed a 16% requirement of NIV support in COVID-19 patients with chronic respiratory diseases [ 19 ]. NIV is suggested in COPD patients (having COVID-19) with acute hypoxemic respiratory failure if oxygen therapy fails [ 23 ]. As patients with COPD have a higher risk of developing a severe COVID-19 disease requiring oxygen therapy, the need for mechanical ventilator support also becomes higher in this group.…”
Background: Although COPD is not one of the most common comorbidities in COVID-19 patients, it can be more fatal in this group. This study aimed to investigate the characteristics and prognosis of COPD patients among the population with COVID-19. Research design and methods: Patients diagnosed with positive PCR test were included in our multicentered, retrospective study. Patients with airway obstruction (previous spirometry) were included in 'COPD group'. Results: The prevalence of COPD in COVID-19 patients was 4.96%(53/1069). There was a significant difference between COPD and non-COPD COVID-19 patients in terms of gender, mean age, presence of dyspnea, tachypnea, tachycardia, hypoxemia and presence of pneumonia. The mortality rate was 13.2% in COPD, 7% in non-COPD patients(p = 0.092). The significant predictors of mortality were higher age, lymphopenia (p < 0.001), hypoxemia (p = 0.028), high D-dimer level (p = 0.011), and presence of pneumonia (p = 0.043) in COVID-19 patients. Conclusions: Our research is one of the first studies investigating characteristics of COPD patients with COVID-19 in Turkey. Although COPD patients had some poor prognostic features, there was no statistical difference between overall survival rates of two groups. Age, status of oxygenization, serum D-dimer level, lymphocyte count and pneumonia were significantly associated parameters with mortality in COVID-19.
“…Figure 3 shows the rest of factors that are significantly associated with the non-survival status according to Table 3: CRP, sodium, WBC, and HGB (neutrophil and lymphocyte are combined into a ratio in Figure 2B and calcium in Figure 2D). All these plots show an interplay between these factors and age i.e., those non-surviving patients are predominately above certain old age; then, higher or lower level of these factors are, with various degrees, associated with the non-survival status (29). All these factors have been discussed in the COVID-19 literature: e.g., CRP, sodium and others, WBC, and HGB (30)(31)(32)(33).…”
Section: Direct Test Of Differences Between Three Groupsmentioning
Aim:The decision of admitting COVID-19 patients as inpatients is mostly determined by chest X-ray based diagnosis of pneumonia severity. However, prognosis of inpatients may diverge into two groups, one group of inpatients did not survive while another group did.Material and Method: More than 100 COVID-19 outpatients are collected from Tokat, Turkey in three categories: outpatients, surviving inpatients, and deceased inpatients. Their blood test profiles are analyzed and compared by dimension reduction techniques and classic statistical tests.
Results:We observe that surviving inpatients share a common blood test profile with the outpatients, whereas non-surviving inpatients are distinctively different. The non-surviving inpatients are on average older. Among patients older than certain age, non-surviving inpatients have higher neutrophil level, lower lymphocyte level (thus higher neutrophil/lymphocyte ratio), lower calcium level, higher C-reactive-protein, sodium, whole blood cell level, andlower hemoglobin level, than the surviving patients (whether these are inpatients or outpatients).
Conclusion:Surviving status is more important than in-and out-patient status in a patient's cluster membership based on blood test profile. This result suggests a plan to use both X-ray diagnosis and blood test results as a criterion to admit COVID-19 inpatients.
“…This scale classifies the frailty severity into nine categories, where advanced categories are associated with a worse prognosis like hospitalizations or death [9], which were more evident in patients with COVID-19 [10]. Independently of the age, frailty has been linked with atypical presentations (functional decline, falls, delirium) [11] and in some cases with an increased in-hospital mortality, days of stay, intensive care unit (ICU) admission, and the need of support with mechanical ventilation [12,13]. This vulnerability is mainly associated with a type 1 interferon (IFN-1) altered response, impaired production of T and B cells, and a secretory phenotype of senescent cells (immunosenescence) [14,15], while considering that older people can be socially vulnerable [16].…”
Frailty is a state of vulnerability to stressors because of a decreased physiological reserve, resulting in poor health outcomes. This state is related to chronic conditions, many of which are risk factors for outcomes in elderly patients having SARS-COV-2. This review aims to describe frailty as a physiological vulnerability agent during the COVID-19 pandemic in elderly patients, summarizing the direct and indirect effects caused by the SARS-COV-2 infection and its prognosis in frail individuals, as well as the interventions and recommendations to reduce their effects. Cohort studies have shown that patients with a Clinical Frailty Scale higher than five have a higher risk of mortality and use of mechanical ventilation after COVID-19; nonetheless, other scales have also associated frailty with longer hospital stays and more severe forms of the disease. Additionally, the indirect effects caused by the pandemic have a negative impact on the health status of older people. Due to the above, a holistic intervention is proposed based on a comprehensive geriatric assessment for frail patients (preventive or post-infection) with emphasis on physical activity and nutritional recommendations, which could be a potential preventive intervention in viral infections by COVID-19.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.